Global R&D Pipeline
My Favorite
Hot Targets:
IL17F
Back
Total number of drugs
15
Phase II and later clinical stages
26.7%
Involving companies
36
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bimekizumab | Bimekizumab | Monoclonal antibody | Immune System Diseases Infectious Diseases Skin and Musculoskeletal Diseases Other Diseases | IL-17A inhibitors IL-17F inhibitors | UCB SA | UCB Pharma SA UCB Biopharma SRL UCB, Inc. Vetter Pharma-Fertigung GmbH & Co. KG UCB Japan Co. Ltd. UCB Australia Pty Ltd. UCB SA UCB, Inc. /Canada/ UCB Korea Co., Ltd. | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia Iceland South Korea Liechtenstein Norway | 2021-08-20 | 2024-07-16 | - | - | - | - | - | Bimekizumab | - | - | detail > | |
| Sonelokimab | Sonelokimab | Nanobody Trispecific antibody | Neoplasms Immune System Diseases Infectious Diseases Mouth and Tooth Diseases Skin and Musculoskeletal Diseases Other Diseases | IL-17A inhibitors IL-17F inhibitors albumin modulators Immunomodulators | Ablynx NV | MoonLake Immunotherapeutics Moonlake Immunotherapeutics AG | Phase 3 | - | - | - | - | - | - | - | - | - | Sonelokimab | - | - | detail > | |
| DMT-310 | DMT-310 | Small molecule drug | Skin and Musculoskeletal Diseases Immune System Diseases | IL-17A inhibitors IL-17F inhibitors | Dermata Therapeutics, Inc. | Dermata Therapeutics, Inc. | Phase 3 | - | - | - | - | - | - | - | - | - | DMT-310 | - | - | detail > | |
| Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) | Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) | Monoclonal antibody | Immune System Diseases Infectious Diseases Skin and Musculoskeletal Diseases | IL-17A inhibitors IL-17F inhibitors | Livzon Pharmaceutical Group, Inc. | Beijing Kanova Biopharmaceutical Co., Ltd. Livzon MABPharm Inc. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) | - | - | detail > | |
| Galvokimig | Galvokimig | Bispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors IL-17A inhibitors IL-17F inhibitors | UCB Biopharma SRL | UCB Biopharma SRL | Phase 1/2 | - | - | - | - | - | - | - | - | - | Galvokimig | - | - | detail > | |
| ORKA-002 | ORKA-002 | Monoclonal antibody | Immune System Diseases Infectious Diseases Skin and Musculoskeletal Diseases | IL-17A inhibitors IL-17F inhibitors | Paragon Therapeutics, Inc. Oruka Therapeutics, Inc. | Oruka Therapeutics, Inc. Paragon Therapeutics, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | ORKA-002 | - | - | detail > | |
| HY-1770 | HY-1770 | Small molecule drug | Immune System Diseases Skin and Musculoskeletal Diseases Congenital Disorders | IL-17A inhibitors IL-17F inhibitors IL-4Rα inhibitors | Suzhou Pharmavan Cancer Research Center Co., Ltd. | Suzhou Pharmavan Cancer Research Center Co., Ltd. | IND Approval | IND Approval | - | - | - | - | - | - | - | - | HY-1770 | - | - | detail > | |
| Oral IL-17 inhibitor(Pepticom) | Oral IL-17 inhibitor(Pepticom) | Chemical drugs | Immune System Diseases | IL-17A inhibitors IL-17F inhibitors | Pepticom Ltd. | Pepticom Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | Oral IL-17 inhibitor(Pepticom) | - | - | detail > | |
| QLS22001 | QLS22001 | Monoclonal antibody | Immune System Diseases | IL-17A inhibitors IL-17F inhibitors | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | QLS22001 | - | - | detail > | |
| Ab-IPL-IL-17 | Ab-IPL-IL-17 | Antibody | Immune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases | IL-17A modulators IL-17F inhibitors | University of Birmingham Enterprise Ltd. | University of Birmingham Enterprise Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | Ab-IPL-IL-17 | - | - | detail > |
Total 15 data
1
2
